TWI426078B - 氮雜苯并噻吩基化合物及使用方法 - Google Patents

氮雜苯并噻吩基化合物及使用方法 Download PDF

Info

Publication number
TWI426078B
TWI426078B TW096130981A TW96130981A TWI426078B TW I426078 B TWI426078 B TW I426078B TW 096130981 A TW096130981 A TW 096130981A TW 96130981 A TW96130981 A TW 96130981A TW I426078 B TWI426078 B TW I426078B
Authority
TW
Taiwan
Prior art keywords
alkyl
group
compound
nhc
formula
Prior art date
Application number
TW096130981A
Other languages
English (en)
Chinese (zh)
Other versions
TW200823222A (en
Inventor
Stephen Price
Karen Williams
Pascal Pierre Savy
Hazel Joan Dyke
John Gary Montana
Mark S Stanley
Liang Bao
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38800915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI426078(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of TW200823222A publication Critical patent/TW200823222A/zh
Application granted granted Critical
Publication of TWI426078B publication Critical patent/TWI426078B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW096130981A 2006-08-21 2007-08-21 氮雜苯并噻吩基化合物及使用方法 TWI426078B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83916306P 2006-08-21 2006-08-21
US87160006P 2006-12-22 2006-12-22
US91762407P 2007-05-11 2007-05-11
US11/894,345 US7893085B2 (en) 2006-08-21 2007-08-20 Aza-benzothiophenyl compounds and methods of use
PCT/US2007/076340 WO2008024724A1 (en) 2006-08-21 2007-08-20 Aza-benzothiophenyl compounds and methods of use

Publications (2)

Publication Number Publication Date
TW200823222A TW200823222A (en) 2008-06-01
TWI426078B true TWI426078B (zh) 2014-02-11

Family

ID=38800915

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096130981A TWI426078B (zh) 2006-08-21 2007-08-21 氮雜苯并噻吩基化合物及使用方法

Country Status (16)

Country Link
US (1) US7893085B2 (enExample)
EP (1) EP2069359B1 (enExample)
JP (1) JP5349306B2 (enExample)
KR (1) KR101475088B1 (enExample)
AR (1) AR062469A1 (enExample)
AU (1) AU2007286807B2 (enExample)
BR (1) BRPI0714629A2 (enExample)
CA (1) CA2660963A1 (enExample)
CL (1) CL2007002431A1 (enExample)
ES (1) ES2528797T3 (enExample)
IL (1) IL197060A (enExample)
MX (1) MX2009001875A (enExample)
NO (1) NO20091198L (enExample)
PE (2) PE20081359A1 (enExample)
TW (1) TWI426078B (enExample)
WO (1) WO2008024724A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660546A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
EP2844655A1 (en) 2012-05-02 2015-03-11 Lupin Limited Substituted pyridine compounds as crac modulators
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CA2890238A1 (en) 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
ES2913213T3 (es) 2017-05-19 2022-06-01 Nflection Therapeutics Inc Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
KR102642411B1 (ko) 2017-05-19 2024-02-28 엔플렉션 테라퓨틱스, 인코포레이티드 피부병 치료를 위한 피롤로피리딘-아닐린 화합물
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US11859252B2 (en) 2017-09-08 2024-01-02 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
IL279977B2 (en) 2018-07-09 2024-06-01 Boehringer Ingelheim Animal Health Usa Inc Heterocyclic anthelmintic compounds
CN117551073A (zh) 2018-11-20 2024-02-13 恩福莱克逊治疗有限公司 用于治疗皮肤疾病噻吩基苯胺化合物
JP7393808B2 (ja) 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン－アニリン化合物
MA55141A (fr) 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés cyanoaryl-aniline pour le traitement d'affections de la peau
WO2020132071A1 (en) 2018-12-19 2020-06-25 Shy Therapeutics. Llc Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
WO2020191091A1 (en) 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic aza-benzothiophene and aza-benzofuran compounds
US11964977B2 (en) 2020-05-29 2024-04-23 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic heterocyclic compounds
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
AU2022377394A1 (en) 2021-11-01 2024-06-13 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic pyrrolopyridazine compounds
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047292A1 (de) * 2003-11-04 2005-05-26 Merck Patent Gmbh Verwendung von thienopyrimidinen
US6987116B2 (en) * 2002-11-25 2006-01-17 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
WO2006106326A1 (en) * 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
US20070049603A1 (en) * 2005-09-01 2007-03-01 Greg Miknis Raf inhibitor compounds and methods of use thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328920A (en) 1991-04-17 1994-07-12 Hoechst-Roussel Pharmaceuticals Incorporated Substituted (pyridinylamino)-indoles
EP0593559A1 (en) 1991-07-05 1994-04-27 MERCK SHARP & DOHME LTD. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
US5214204A (en) 1991-07-19 1993-05-25 Abbott Laboratories Arylamidoalkyl-n-hydroxyurea compounds having lipoxygenase inhibitory activity
EP0530537B1 (en) 1991-08-12 1997-01-08 Takeda Chemical Industries, Ltd. Condensed pyrimidine derivatives, their production and use as antitumor agents
CA2083891A1 (en) 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
JPH05345780A (ja) 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
US5852046A (en) 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
US5350748A (en) 1993-08-18 1994-09-27 Warner-Lambert Company 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion
DE4425609A1 (de) 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
WO1998047894A1 (en) 1997-04-24 1998-10-29 Dow Agrosciences Llc Pesticidal 3-(substituted phenyl)-5-(thienyl or furyl)-1,2,4-triazoles
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
FR2777886B1 (fr) 1998-04-27 2002-05-31 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6436964B1 (en) 1998-06-30 2002-08-20 Eli Lilly And Company Piperidine derivatives having effects on serotonin related systems
CA2335310A1 (en) 1998-06-30 2000-01-06 Kenneth Lee Hauser Azepine derivatives having effects on serotonin related systems
AU4850199A (en) 1998-06-30 2000-01-17 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
US6410562B1 (en) 1998-12-18 2002-06-25 Eli Lilly And Company Hypoglycemic imidazoline compounds
HUP0105113A3 (en) * 1999-01-13 2004-11-29 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds
JP2000204079A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
FR2799756B1 (fr) 1999-10-15 2001-12-14 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR027133A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
EE05450B1 (et) * 2000-07-19 2011-08-15 Warner-Lambert Company 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6653346B1 (en) 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
MXPA04008152A (es) 2002-02-19 2005-09-08 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
AR038972A1 (es) 2002-03-13 2005-02-02 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek
PL401638A1 (pl) * 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
US20040009976A1 (en) 2002-04-30 2004-01-15 Kumiko Takeuchi Hypoglycemic imidazoline compounds
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
US7091216B2 (en) 2002-08-02 2006-08-15 Merck & Co., Inc. Substituted furo[2,3-b]pyridine derivatives
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005104838A (ja) 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
SI1663242T1 (sl) 2003-08-07 2011-09-30 Rigel Pharmaceuticals Inc 2,4-pirimidindiaminske spojine in uporabe kot antiproliferativna sredstva
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005054176A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
EP1694663A1 (en) 2003-12-19 2006-08-30 Biovitrum Aktiebolag Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
ES2338060T3 (es) 2003-12-22 2010-05-03 Basilea Pharmaceutica Ag Componentes de tipo ariloxi y ariltoxia-cetofenona para el tratamiento del cancer.
MXPA06007213A (es) 2003-12-23 2006-08-18 Pfizer Prod Inc Combinacion terapeutica para la mejora de la cognicion y trastornos sicoticos.
CA2660546A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
CA2662285A1 (en) 2006-08-31 2008-03-06 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987116B2 (en) * 2002-11-25 2006-01-17 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
WO2005047292A1 (de) * 2003-11-04 2005-05-26 Merck Patent Gmbh Verwendung von thienopyrimidinen
WO2006106326A1 (en) * 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
US20070049603A1 (en) * 2005-09-01 2007-03-01 Greg Miknis Raf inhibitor compounds and methods of use thereof

Also Published As

Publication number Publication date
AR062469A1 (es) 2008-11-12
AU2007286807A1 (en) 2008-02-28
US7893085B2 (en) 2011-02-22
KR101475088B1 (ko) 2014-12-23
PE20081359A1 (es) 2008-11-27
EP2069359B1 (en) 2014-11-12
US20080081821A1 (en) 2008-04-03
AU2007286807B2 (en) 2013-03-21
BRPI0714629A2 (pt) 2013-05-07
ES2528797T3 (es) 2015-02-12
NO20091198L (no) 2009-05-20
JP5349306B2 (ja) 2013-11-20
IL197060A0 (en) 2009-11-18
KR20090047538A (ko) 2009-05-12
MX2009001875A (es) 2009-03-02
CL2007002431A1 (es) 2008-03-14
IL197060A (en) 2014-12-31
JP2010501584A (ja) 2010-01-21
CA2660963A1 (en) 2008-02-28
PE20120049A1 (es) 2012-02-16
TW200823222A (en) 2008-06-01
EP2069359A1 (en) 2009-06-17
WO2008024724A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
TWI426078B (zh) 氮雜苯并噻吩基化合物及使用方法
TWI411614B (zh) 氮雜苯并呋喃基化合物及使用方法
EP2231662B1 (en) 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
EP2307364B1 (en) Isoindolone derivatives as mek kinase inhibitors and methods of use
EP2222675B1 (en) 5-anilinoimidazopyridines and methods of use
EP2220092B1 (en) Azaindolizines and methods of use
RU2483069C2 (ru) Азаиндолизины и способы их применения
RU2444524C2 (ru) Азабензотиофенильные соединения и способы применения

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees